Ads
related to: 23 & me genetic testingdnaweekly.com has been visited by 10K+ users in the past month
Search results
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
KAAL Austin· 6 days agoStocks that are trading heavily or have substantial price changes on Friday: Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall.
Natera (NASDAQ:NTRA) Price Target Raised to $130.00
ETF DAILY NEWS· 2 days agoNatera (NASDAQ:NTRA – Free Report) had its target price boosted by Canaccord Genuity Group from $100.00 to $130.00 in a research note issued to investors on Friday, Benzinga reports. Canaccord ...
Long-term study finds organic farming leads to adaptations in the genetic material in plants
Phys.org· 3 days agoThe researchers planted barley plants on two neighboring fields and used conventional farming...
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
Zacks via Yahoo Finance· 2 days agoHims & Hers Heath stock has increased 19.7% in the past year. Earnings estimates for the company...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for...
Morningstar· 2 days agoTOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Her father's death fuels a lifelong push to understand South Asian heart health
San Francisco Chronicle· 24 hours agoDr. Latha Palaniappan, an internal medicine doctor and professor of cardiovascular medicine at...
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
The Yuma Sun· 7 days agoSALT LAKE CITY, May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
Zacks· 3 days agoFree Report) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This quarterly report represents an earnings surprise of -8.33%. Over the ...
BridgeBio Pharma (NASDAQ:BBIO) Upgraded by Evercore ISI to “Strong-Buy”
ETF DAILY NEWS· 7 hours agoEvercore ISI upgraded shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) to a strong-buy rating in a research report released on Monday, Zacks.com reports. Several other analysts have also ...
How Rochester medical research events will help you discover your ancestry, health risks
Democrat and Chronicle via Yahoo News· 7 days agoHealth care crises: Mental health care needs spiked 23% in NY as treatment capacity dropped 10% What...
